HC Wainwright Has Negative Forecast for Nuvalent Q1 Earnings

Nuvalent, Inc. (NASDAQ:NUVL) – Equities research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of Nuvalent in a report issued on Monday, March 3rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.21) for the quarter, down from their prior forecast of ($1.08). HC Wainwright currently has a “Buy” rating and a $110.00 target price on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. HC Wainwright also issued estimates for Nuvalent’s Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.12) EPS, FY2025 earnings at ($4.66) EPS and FY2026 earnings at ($3.26) EPS.

A number of other equities research analysts also recently commented on the stock. Wedbush reiterated an “outperform” rating and set a $115.00 price target on shares of Nuvalent in a report on Monday, January 13th. BMO Capital Markets lifted their target price on shares of Nuvalent from $132.00 to $134.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Nuvalent presently has an average rating of “Moderate Buy” and a consensus target price of $113.10.

Nuvalent Trading Up 0.5 %

Nuvalent stock opened at $71.99 on Wednesday. The stock has a market cap of $5.12 billion, a PE ratio of -20.75 and a beta of 1.38. The stock has a 50-day moving average price of $79.68 and a 200 day moving average price of $88.40. Nuvalent has a 52 week low of $61.80 and a 52 week high of $113.51.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings results on Thursday, February 27th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02).

Insider Activity

In other Nuvalent news, CFO Alexandra Balcom sold 4,016 shares of Nuvalent stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $79.68, for a total transaction of $319,994.88. Following the transaction, the chief financial officer now directly owns 61,734 shares of the company’s stock, valued at $4,918,965.12. The trade was a 6.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Matthew Shair sold 2,000 shares of the stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $83.78, for a total transaction of $167,560.00. Following the completion of the sale, the director now directly owns 220,522 shares of the company’s stock, valued at $18,475,333.16. The trade was a 0.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 110,800 shares of company stock valued at $8,895,004 in the last ninety days. Company insiders own 12.52% of the company’s stock.

Institutional Trading of Nuvalent

A number of institutional investors have recently added to or reduced their stakes in NUVL. Creative Planning purchased a new stake in shares of Nuvalent in the third quarter worth about $232,000. Harbor Capital Advisors Inc. boosted its holdings in Nuvalent by 29.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 21,516 shares of the company’s stock worth $2,201,000 after acquiring an additional 4,957 shares during the period. AlphaCentric Advisors LLC purchased a new position in Nuvalent in the 3rd quarter worth approximately $716,000. State of New Jersey Common Pension Fund D acquired a new stake in Nuvalent in the third quarter valued at approximately $2,412,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Nuvalent during the third quarter valued at approximately $490,000. 97.26% of the stock is owned by hedge funds and other institutional investors.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.